The role of miR-150 in normal and malignant hematopoiesis

He, Yanyu; Jiang, Xi; Chen, Jianjun

doi:10.1038/onc.2013.346

Cited by 121 publications

(116 citation statements)

References 66 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…Among these, microRNA-150 warranted further investigation for a number of reasons. This microRNA plays an important role in normal and malignant hematopoiesis (15). In addition, plasma (14) and cellular (16,17) microRNA-150 were both downregulated in poor prognosis CLL patients based on ZAP70 and IgHV mutational status.…”

Section: Introductionmentioning

confidence: 97%

Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia

Stamatopoulos

Damme

Crompot

et al. 2015

Mol Med

View full text Add to dashboard Cite

Recently, extracellular circulating microRNAs were also detected in body fluids, such as serum, plasma, saliva and urine (7). These circulating microRNAs are believed to be chaperoned by various carriers, such as secreted mem- MicroRNAs (or miRs) play a crucial role in chronic lymphocytic leukemia (CLL) physiopathology and prognosis. In addition, circulating microRNAs in body fluids have been proposed as new biomarkers. We investigated the expression of matched cellular and serum circulating microRNA-150 by quantitative real-time PCR (qPCR) from purified CD19 + cells or from CLL serums obtained at diagnosis in a cohort of 273/252 CLL patients with a median follow-up of 78 months (range 7-380) and correlated it to other biological or clinical parameters. We showed that miR-150 was significantly overexpressed in CLL cells/serums compared with healthy subjects (P < 0.0001). Among CLL patients, a low cellular miR-150 expression level was associated with tumor burden, disease aggressiveness and poor prognostic factors. In contrast, a high level of serum miR-150 was associated with tumor burden markers and some markers of poor prognosis. Similarly, cellular and serum miR-150 also predicted treatment-free survival (TFS) and overall survival (OS) in an opposite manner: patients with low cellular/serum miR-150 levels have median TFS of 40/111 months compared with high-level patients who have a median TFS of 122/60 months (P < 0.0001/P = 0.0066). Similar results were observed for OS. We also found that cellular and serum miR-150 levels vary in an opposite manner during disease progression and that cellular miR-150 could be regulated by its release into the extracellular space. Cellular and serum levels of miR-150 are associated with opposite clinical prognoses and could be used to molecularly monitor disease evolution as a new prognostic factor in CLL. brane vesicles (exosomes from 50 to 100 nm and microvesicles from 100 nm to 1 μm) or protein/lipid complexes (8,9), since carrier-free microRNAs will be degraded by RNase digestion and other environmental factors (9). Their levels and composition have been shown to be modulated with injury conditions as well as tumor burden (10-12). For these reasons, extracellular microRNAs could be used as informative biomarkers to assess and monitor disease evolution (11,13). Moussay et al. (14) recently observed that some circulating microRNAs in CLL plasma could be used as prognostic factors. Among these, microRNA-150 warranted further investigation for a number of reasons. This microRNA plays an important role in normal and malignant hematopoiesis (15). In addition, plasma (14) and cellular (16,17) microRNA-150 were both downregulated in poor prognosis CLL patients based on ZAP70 and IgHV mutational status. A low level of cellular microRNA-150 was also observed in CLL proliferation centers (18), and microRNA-150 is differentially expressed according to the stereotyped B-cell receptor (BCR) subset taken into consideration (19), emphasizing its pivotal role in CLL. Finally, a recent s...

show abstract

Section: Introductionmentioning

confidence: 97%

Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia

Stamatopoulos

Damme

Crompot

et al. 2015

Mol Med

View full text Add to dashboard Cite

show abstract

“…Monticelli et al were the first to investigate the systematic miRNA gene profiling in hematopoietic cells, demonstrating that its profiling was different from non-hematopoietic cells (15). As an important hematopoietic cell-specific miRNA, miR-150 is mainly expressed in B-cells, T-cells and natural killer cells, and plays a critical role in the differentiation of numerous hematopoietic cell lineages, particularly in lymphocyte development and function (14,16). In addition, a recent study has identified that serum circulating miR-150 is a sensor of general lymphocyte activation and may serve as a biomarker of human lymphocyte activation in healthy and disease conditions (17).…”

Section: Role Of Microrna-150 In Solid Tumors (Review)mentioning

confidence: 99%

“…The role of miR-150 in normal and malignant hematopoiesis has been summarized in detail in a review article by He et al (14). In the present review, the functions and regulatory mechanism of miR-150 as an oncogene or tumor suppressor gene in certain solid tumors were discussed.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, a recent study has identified that serum circulating miR-150 is a sensor of general lymphocyte activation and may serve as a biomarker of human lymphocyte activation in healthy and disease conditions (17). miR-150 has been previously reported to be differentially expressed in various hematopoietic cell lineages of a specific developmental stage or characteristically up-or downregulated in various types of hematopoietic malignancies, including leukemia, lymphoma and myelodysplastic syndrome (14). In chronic myeloid leukemia (CML), miR-150 has been demonstrated to be involved in the mechanism of apoptosis induced by cisplatin in the human CML cell line, K562 (18).…”

Section: Role Of Microrna-150 In Solid Tumors (Review)mentioning

confidence: 99%

See 1 more Smart Citation

Role of microRNA-150 in solid tumors

2015

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs) are a family of small endogenous noncoding RNAs and their altered expression has been associated with various cellular functions, including cell development, proliferation, differentiation, apoptosis, signal transduction, tumorigenesis and cancer progression. Accumulating evidence has indicated that miRNA (miR)-150 plays an essential regulatory role in normal hematopoiesis and tumorigenesis; therefore, miR-150 may be a potential biomarker and therapeutic target in the diagnosis and treatment of various malignancies. The aim of the present review was to summarize the current knowledge on the functions and regulatory mechanism of miR-150 as an oncogene or tumor suppressor gene in solid tumors. In addition, its potential application as a tumor biomarker, targeted therapeutic strategy and index of prognosis in various cancer types was investigated.

show abstract

“…He et al, (2014). The presence of HSCs and their exposure to hemopoietic growth factors prompt the original division and differentiation into common myeloid and lymphoid progenitors, while at least one daughter cell remains an HSC, allowing the process to continue.…”

Section: Tissuesmentioning

confidence: 99%